Clinicalinhibitors of IL-6 signaling, including tocilizumab, have shown significant effectivenessin the treatment of several inflammatory rheumatic diseases, including rheumatoidarthritis and juvenile idiopathic arthritis; accordingly, anti-IL-6 agents may potentiallyrepresent future promising therapies for the treatment of PP. The gene discussed is IL6; the disease is juvenile idiopathic arthritis.